Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036621 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00036621: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00036621 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036621, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
This clinical trial will assess whether BMS-275291 can be administered safely in combination with standard adjuvant therapy for early breast cancer and whether plasma concentrations at trough exceed a target minimum.
Interventions
- DRUG BMS-275291
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Why NCT00036621 stopped before completion
NCT00036621 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which BMS-275291 is the first listed.
NCT00036621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036621 about?
NCT00036621 is a clinical study titled "A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy". This clinical trial will assess whether BMS-275291 can be administered safely in combination with standard adjuvant therapy for early breast cancer and whether plasma concentrations at trough exceed a target minimum.
What is the current status of trial NCT00036621?
This trial is currently terminated. It is a Phase 2 study.
What interventions are being tested in trial NCT00036621?
The interventions under investigation include: BMS-275291 (DRUG).
Who is sponsoring clinical trial NCT00036621?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.